TRIAMINIC MULTI-SYMPTOM FEVER OTC
Generic Name and Formulations:
Dextromethorphan HBr 7.5mg, chlorpheniramine maleate 1mg, acetaminophen 160mg; per 5mL; alcohol-free; bubble gum-flavored liq; contains sodium 6mg/5mL.
Novartis Consumer Health
Indications for TRIAMINIC MULTI-SYMPTOM FEVER:
Cough, fever, sore throat, allergy symptoms, headache, minor aches and pains.
<4yrs: do not use. 4–6yrs: individualize. 6–12yrs: 10mL every 6 hours as needed; max 4 doses/24 hours.
Children <4yrs old. During or within 14 days of MAOIs. Concomitant other acetaminophen products. For use as a sedative hypnotic.
Liver disease. Glaucoma. Asthma. Lower respiratory disorders. Discontinue if symptoms worsen or persist for ≥3 days.
Antitussive + antihistamine + analgesic.
See Contraindications. Hypertensive crisis with MAOIs. Increased CNS effects with other CNS depressants.
Drowsiness, anticholinergic effects, excitability in children, hepatotoxicity (overdosage).
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- Handling Chemotherapy Premedications
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|